Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 106

1.

Risk factors for cardiovascular disease in children infected with human immunodeficiency virus-1.

Miller TL, Orav EJ, Lipshultz SE, Arheart KL, Duggan C, Weinberg GA, Bechard L, Furuta L, Nicchitta J, Gorbach SL, Shevitz A.

J Pediatr. 2008 Oct;153(4):491-7. doi: 10.1016/j.jpeds.2008.04.016. Epub 2008 Jun 9.

2.

Impact of protease inhibitor substitution with efavirenz in HIV-infected children: results of the First Pediatric Switch Study.

McComsey G, Bhumbra N, Ma JF, Rathore M, Alvarez A; First Pediatric Switch Study.

Pediatrics. 2003 Mar;111(3):e275-81.

PMID:
12612284
3.

Changes in lipid profile over 24 months among adults on first-line highly active antiretroviral therapy in the home-based AIDS care program in rural Uganda.

Buchacz K, Weidle PJ, Moore D, Were W, Mermin J, Downing R, Kigozi A, Borkowf CB, Ndazima V, Brooks JT.

J Acquir Immune Defic Syndr. 2008 Mar 1;47(3):304-11.

PMID:
18398971
4.
5.

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study.

Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM Jr.

JAMA. 1998 May 27;279(20):1615-22.

PMID:
9613910
6.

Prevalence of dyslipidemia among human immunodeficiency virus infected Nigerians.

Muhammad S, Sani MU, Okeahialam BN.

Ann Afr Med. 2013 Jan-Mar;12(1):24-8. doi: 10.4103/1596-3519.108246.

7.

Impact of HIV infection and HAART on serum lipids in men.

Riddler SA, Smit E, Cole SR, Li R, Chmiel JS, Dobs A, Palella F, Visscher B, Evans R, Kingsley LA.

JAMA. 2003 Jun 11;289(22):2978-82.

PMID:
12799406
8.

Protease inhibitor-based HAART, HDL, and CHD-risk in HIV-infected patients.

Asztalos BF, Schaefer EJ, Horvath KV, Cox CE, Skinner S, Gerrior J, Gorbach SL, Wanke C.

Atherosclerosis. 2006 Jan;184(1):72-7. Epub 2005 Jun 1.

PMID:
15935358
9.

Longitudinal changes in serum lipids among HIV-infected men on highly active antiretroviral therapy.

Riddler SA, Li X, Chu H, Kingsley LA, Dobs A, Evans R, Palella F, Visscher B, Chmiel JS, Sharrett A.

HIV Med. 2007 Jul;8(5):280-7.

10.

Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy.

Chantry CJ, Hughes MD, Alvero C, Cervia JS, Meyer WA 3rd, Hodge J, Borum P, Moye J Jr; PACTG 1010 Team.

Pediatrics. 2008 Jul;122(1):e129-38. doi: 10.1542/peds.2007-2467. Epub 2008 Jun 2.

11.

Hepatitis C infection is associated with lower lipids and high-sensitivity C-reactive protein in HIV-infected men.

Floris-Moore M, Howard AA, Lo Y, Schoenbaum EE, Arnsten JH, Klein RS.

AIDS Patient Care STDS. 2007 Jul;21(7):479-91.

12.

HIV, HAART, and lipoprotein particle concentrations in the Women's Interagency HIV Study.

Tien PC, Schneider MF, Cox C, Cohen M, Karim R, Lazar J, Young M, Glesby MJ.

AIDS. 2010 Nov 27;24(18):2809-17. doi: 10.1097/QAD.0b013e32833fcb3b.

13.

Treatment with highly active antiretroviral therapy in human immunodeficiency virus type 1-infected children is associated with a sustained effect on growth.

Verweel G, van Rossum AM, Hartwig NG, Wolfs TF, Scherpbier HJ, de Groot R.

Pediatrics. 2002 Feb;109(2):E25.

PMID:
11826235
14.

Marked dyslipidemia in human immunodeficiency virus-infected children on protease inhibitor-containing antiretroviral therapy.

Lainka E, Oezbek S, Falck M, Ndagijimana J, Niehues T.

Pediatrics. 2002 Nov;110(5):e56.

PMID:
12415062
15.

Serum lipids, glucose homeostasis and abdominal adipose tissue distribution in protease inhibitor-treated and naive HIV-infected children.

Bitnun A, Sochett E, Babyn P, Holowka S, Stephens D, Read S, King SM.

AIDS. 2003 Jun 13;17(9):1319-27.

PMID:
12799553
16.

Nutritional assessment and lipid profile in HIV-infected children and adolescents treated with highly active antiretroviral therapy.

Tremeschin MH, Sartorelli DS, Cervi MC, Negrini BV, Salomão RG, Monteiro JP.

Rev Soc Bras Med Trop. 2011 May-Jun;44(3):274-81. Epub 2011 Jul 1.

17.

Metabolic syndrome in HIV-infected patients from an urban, midwestern US outpatient population.

Mondy K, Overton ET, Grubb J, Tong S, Seyfried W, Powderly W, Yarasheski K.

Clin Infect Dis. 2007 Mar 1;44(5):726-34. Epub 2007 Jan 22.

18.

Lipid and glucose alterations in perinatally-acquired HIV-infected adolescents and young adults.

Blázquez D, Ramos-Amador JT, Saínz T, Mellado MJ, García-Ascaso M, De José MI, Rojo P, Navarro ML, Muñoz-Fernández MÁ, Saavedra J, Roa MA, Jiménez S, Beceiro J, Prieto L, Hortelano MG, González-Tomé MI.

BMC Infect Dis. 2015 Mar 8;15:119. doi: 10.1186/s12879-015-0853-8.

20.

Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.

Friis-Møller N, Weber R, Reiss P, Thiébaut R, Kirk O, d'Arminio Monforte A, Pradier C, Morfeldt L, Mateu S, Law M, El-Sadr W, De Wit S, Sabin CA, Phillips AN, Lundgren JD; DAD study group.

AIDS. 2003 May 23;17(8):1179-93.

PMID:
12819520

Supplemental Content

Support Center